PATENT CLAIM ANALYSIS

Application Number: 16112008
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "139100"]

Abstract:
Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

Claim (Index 13):
The method according to  claim 11 , wherein the cancer is selected from the group consisting of melanoma, kidney cancer, renal carcinoma, bladder cancer, EBV-positive cancer and HPV-positive cancer.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 96.0
- Lexical Diversity: 1.4
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15922921', '15229336', '15750425', '15908218', '15495048']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8899103269993153
- 35 USC 102 Novelty (BERT): 0.7117593746984696
- Combined Prediction Score: 0.8720952317692308
- Mean Citation Score: 841.4670800000001
- Max Citation Score: 971.493
- Similarity Product: 745.2085741608739

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test